Pharmacodynamic Characterization of Dienogest

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

September 30, 2009

Conditions
Pharmacodynamics
Interventions
DRUG

Dienogest (81150037)

daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days

DRUG

Dienogest (81150231)

daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days

DRUG

Dienogest (SH T00660A)

daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days

DRUG

Dienogest (81150746)

daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days

Trial Locations (1)

9713 GZ

Groningen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00754871 - Pharmacodynamic Characterization of Dienogest | Biotech Hunter | Biotech Hunter